Log In
BCIQ
Print this Print this
 

ATryn

Also known as: rhAT

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionRecombinant human antithrombin (rhAT)
Molecular Target Not available
Mechanism of ActionAnti-thrombotic/thrombolytic
Therapeutic ModalityBiologic: Protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$921.0M

$621.0M

$300.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/13/2010

$21.0M

$21.0M

0

03/19/2009

$900.0M

$600.0M

$300.0M

Get a free BioCentury trial today